BPH Global Ltd
AASX:BP80.01
AUD
+0.00
(+18.18%)
ISIN
AU0000284366
Return %
Stock
S&P 500
1Y
-35.00
14.20
3Y
-87.00
81.12
5Y
-98.03
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Matthew Leonard
- Full Time Employees
- 31
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 365 Little Collins Street Melbourne VIC Australia 3000
- IPO Date
- Apr 3, 2000
- Website
- bphglobal.com.au
- Similar Companies
- Business
- BPH Global Ltd is a plant-based biotechnology company focused on sourcing, developing, producing, and commercializing traditional medicine-inspired products; it operates across food, nutrition, health supplements, cosmetics, and personal care segments with a portfolio that includes birds’ nest derivatives, seaweed and other marine plant-based products, and cannabidiol (CBD) components. The company maintains a diversified product lineup that spans raw birds’ nest products, processed birds’ nest offerings, sea grapes and seaweed-derived ingredients, plant-based nutraceuticals, and CBD-related ingredients, delivered through multiple brands and formulation types. Latest major company changes include ongoing expansion of research and development collaborations, strategic joint ventures and exclusive agreements for new product development, acquisitions of related biotechnology firms to broaden manufacturing and distribution capabilities, and initiatives to grow sales and distribution footprints in China and across Southeast Asia. The firm has pursued corporate restructurings and leadership appointments to support its growth trajectory, including governance enhancements and the integration of acquired entities into its operating framework, alongside notable product launches in the birds’ nest extracts, honey-infused formulations, and other TCMed-inspired offerings. Industry and business segments: biotechnology and plant-based wellness; traditional Chinese medicine-based health outcomes; product development, production, and commercialization; nutraceuticals, pharmaceuticals, cosmetics, and personal care ingredients. Target markets include China, Singapore, Australia, and broader Southeast Asia, with customers spanning B2B bulk buyers, distributors, and direct-to-consumer channels through partner networks. Geographic operations: Asia-Pacific focus with activities in Singapore, Malaysia, China, and Australia, and collaborations with regional mariculture and biotech facilities. Founding year and headquarters: established in 1984 and headquartered in Melbourne, Australia, with a Singaporean research facility and other regional subsidiaries supporting global operations. Subsidiaries and parent relationships: operates through multiple subsidiaries and joint ventures, including local manufacturing, R&D facilities, and distribution entities across Singapore, Foshan, Hainan, and related markets; maintains relationships with parent and affiliate groups to coordinate strategy and product development across its plant-based biotechnology portfolio.